

Machine learning applications and challenges

In the medical domain

Kaustubh R. Patil
k.patil@fz-juelich.de


Applied Machine Learning
Institute of Neuroscience and Medicine
INM-7: Brain and Behaviour
Research Centre Jülich

Institute of Systems Neuroscience
Heinrich Heine University Düsseldorf


Brain-behavior data:
structural, functional,
diffusion, meta-analytic,
symptoms, cognition




Machine-learning methods:
classification
clustering
factorization



Prediction of phenotypes
(brain-age and size, sex,
WM), and clinical status
(SCSZ, PD)



Biological insights of clinical
relevance and evolutionary
origins



Multi-modal organization
in health and disease


***“We become what we behold.
We shape our tools and then our tools shape us.”***



Marshall McLuhan


Winnipeg Free Press

What is ML/AI?



Hahn et. al, 2017 Mol. Psych.

Since 60s: so why now?



Lots of data



<https://cs.stanford.edu/people/karpathy/cnnembed/>



Fast computers




<http://www.fz-juelich.de>




Good
Learning
Algorithms



Deep neural networks



Utopia?





We can accurately predict sex of a new subject from region-wise FC profiles
(SVM, nested optimization, between-sample prediction, N=434/310)

LETTER | VOLUME 21, ISSUE 12, P989-991, DECEMBER 01, 2016

Machine Learning for Plant Phenotyping Needs Image Processing

Sotirios A. Tsaftaris · Massimo Minervini · Hanno Scharf

DOI: <https://doi.org/10.1016/j.tplants.2016.10.002>




Trends in Plant Science

Letter | Published: 07 January 2019

Identifying facial phenotypes of genetic disorders using deep learning

Yaron Gurovich · Yair Hanani, Omri Bar, Guy Nadav, Nicole Fleischer, Dekel Gelbman, Lina Basel-Salmon, Peter M. Krawitz, Susanne B. Kamphausen, Martin Zenker, Lynne M. Bird & Karen W. Gripp


Nature Medicine 25, 60–64 (2019) | [Download Citation](#)



Dystopia?

The New York Times

Inside China's Dystopian Dreams: A.I., Shame and Lots of Cameras



A video showing facial recognition software in use at the headquarters of the artificial intelligence company Megvii in Beijing.
Gilles Sabrie for The New York Times

By Paul Mozur

<https://www.nytimes.com/2018/07/08/business/china-surveillance-technology.html>

Forbes

Billionaires

Innovation

Leadership

Money

Consumer

Industry

27,552 views | Jan 14, 2019, 12:51am

The Weaponization Of Artificial Intelligence



Jayshree Pandya Contributor

COGNITIVE WORLD Contributor Group


AI & Big Data

Jayshree Pandya is Founder of Risk Group & Host of Risk Roundup.

f

t

in






The reality of the rise of autonomous weapons systems SHUTTERSTOCK ENHANCED BY COGWORLD

<https://www.forbes.com/sites/cognitiveworld/2019/01/14/the-weaponization-of-artificial-intelligence/#20d4a6873686>

www.helmholtz.de

**Knowledge on
brain organization:
functional neuroanatomy**

**Machine-learning to predict
behavioral or clinical
phenotypes from MRI-data**



Outline

- Machine learning
- Sex classification: replication
- Schizophrenia sybtypes: data separation

Machine learning: why to use it?

Machine learning is not magic; it can't get something from nothing. (Domingos, 2012)


Patterns are often more informative than individual variables

- e.g. any logical function
- Univariate methods cannot identify those
 - Multiple testing correction issue (lower power)

Generalizable solutions that work on unseen data

- Fewer false positives (not guaranteed)
- Predictive analytics
- Practical applications: e.g. clinical status/score prediction

Machine learning





“The fundamental goal of machine learning is to generalize beyond the examples in the training set. This is because, no matter how much data we have, it is very unlikely that we will see those exact examples again at test time.” (Domingos, 2012, A Few Useful Things to Know about Machine Learning)

Challenge: Generalization (avoid over-fitting)

- **The fundamental goal of machine learning is to generalize beyond the examples in the training set. This is because, no matter how much data we have, it is very unlikely that we will see those exact examples again at test time. (Domingos, 2012)**
- But we only one dataset!
- Fit on the complete data
 - Model describes the „training“ data well
 - Fails to generalize on „unseen“ data

K-fold cross-validation


Estimate performance on “unseen” data



This becomes part of the model.
Mean-centering, Z-score, PCA etc. applied only to the training data.
The parameters should be retained and applied to the test data.

Predict biological traits / clinical status using neuroimaging data

- **Aim:** Generalization models
- **Aim:** Interpretable results
- **Data:** Resting-state data
 - Easy to acquire
 - Intrinsic properties of brain function
- **Issue:** High dimensions
 - Leads to over-fitting



Issue 1: High dimensions

- Over-fitting
 - Curse of dimensionality
- Results might not be interpretable
- **... our intuitions, which come from a three-dimensional world, often do not apply in high-dimensional ones. (Domingos, 2012)**

Our approach

a priori feature reduction: parcel-wise or pre-defined networks


Whole-brain analysis

- Too many features
 - 200 nodes: ~20,000 features
 - #features >> #subjects
- Machine learning
 - Need for feature selection
 - Accuracy can suffer
- Interpretation is difficult


Parcel/Network-based analysis

- Reasonable number of features
 - 200 nodes: ~200 features
 - #features > #subjects
- Machine learning
 - *a priori* feature selection
 - Better predictions
- Interpretable results

Parcel-based classification



Mapping fingerprint – phenotype relationships





Accurate prediction sex of a new subject from region-wise FC profiles
(SVM, nested optimization, between-sample prediction, N = 434 / 310)

Cross-sample prediction: generalization check



Weis, Patil et. al,
Sex Classification by
Resting State Brain
Connectivity,
Cerebral Cortex 2019



Similar performance on
other datasets.
Solution is
generalizable. ✓

Sample 1 and 2 = Human Connectome Project




Sample 3 = FZJ 1000 brains study



Issue 2: Double-dipping (limited data)

- Over-fitting
 - Data-leakage
- Misleading results (false positives)



Our approach

Two-step solution

Step 1: Symptomatology

- Subtypes
 - Clinical symptom scales
 - Factorization
 - Clustering analysis

Step 2: Neuroimaging


- Resting-state data
- Subtypes from Step 1
- Cross-validation analysis
- Interpretable results

Mapping fingerprint – pathology relationships


Step 1: Symptomatology → Groups

Robust low-rank
description of SCZ
psychopathology
from >2000 patients

Two core phenotypical
subtypes



Orthogonal Non-Negative
Matrix Factorization





K-means
Gaussian Mixture Modelling

Schizophrenia subtypes and brain basis

Step 2: Groups → Brain regions

Chen, Patil et. al,
Neurobiological divergence of the positive and
negative schizophrenia subtypes identified upon
a new factor-structure of psychopathology using
non-negative factorization: An international
machine-learning study,
Biological Psychiatry 2019 (accepted)

Ji Chen



Whole brain connectome classification accuracy: 0.57

Regional FC profiles support
subtype discrimination

Other issues

- **Feature selection / construction**
 - “Over-optimization is root of all non-generalization”
 - Solutions are often over-fitted
- **Data privacy**
 - Fingerprint analysis
 - 95% identification with high quality scan
 - Deep networks can retain too much information
- **... developing successful machine learning applications requires a substantial amount of “black art” that is difficult to find in textbooks. (Domingos, 2012)**

Thank you!



Funding



HELMHOLTZ

RESEARCH FOR GRAND CHALLENGES



Rank Selection in Non-negative Matrix Factorization




Muzzarelli, Weis, Eickhoff & Patil,
Rank Selection in Non-negative
Matrix Factorization: Systematic
Comparison and a New MAD Metric
IJCNN 2019

- Non-Negative Matrix Factorization
 - Powerful dimensionality reduction
 - Rank Selection Problem
- Rank Selection Methods
 - Stability vs. imputation
 - Our proposal: MADimput
- Data properties impact rank selection
 - Sparsity
 - Intrinsic dimensionality

Non-negative matrix Factorization (NMF)

Basic properties of NMF




$$\|V - WH\|_2 \quad \text{subject to } W \geq 0, H \geq 0$$

interpretability

part-based representation

Rank selection problem

Need to find dimensionality of reduced representation



Crucial to select “best” rank
mostly when no prior knowledge

what is “best”
& which metric to use?

Rank selection approaches

Stability – based

Perform multiple NMF runs at each rank

Check stability of factor matrix

does NOT ensure accuracy

degeneracy

Imputation – based



Exclude random data points in multiple CV runs

Compute reconstruction error in imputed points

Calculates Accuracy

Our proposal: MADimput in ImputationCV

Good reconstruction, and homogeneous



Systematic evaluation

Performance comparison of 6 metrics

Stability

- Consensus
 - coph** - cophenetic coefficient
 - disp** - dispersion
- Stability in split-half CV
 - aRI** - adjusted Rand Index
 - inner** - inner product

Imputation

- MSE** - mean of MSE in CV runs
- MAD** - MAD of MSE in CV runs


Permutation of underlying distribution

- perm** – error slope comparison with permuted data


Effect of data properties

Simulated data : Manipulation **sparsity** + **latent dimensionality**


sparse



dense




Results: Simulated data dense



Only imputation
methods are accurate
(but struggle at low true rank)

Results: Simulated data sparse



Imputation, permutation
and aRI methods
have good performance,


but all struggle at higher
rank

Real data: sources




MED5 - medical abstracts

1159 terms x 124 abstracts
5 underlying human-labelled topics



dig0246 – handwritten digits recognition


64 attributes and 1520 samples representing digits {0, 2, 4, 6}
→ true rank: 4



ALL-AML – cancer gene expression

5000 genes x 38 samples
2 (more?) myeloma types

Results: Real data




MADimput, aRI and
consensus methods
close to expected true
rank

but consensus methods
failed badly in simulated !
→ false hit for low rank ?

NMF rank selection: discussion

- No method is perfect, and most are just bad
 - No methods works best in all data type & dimensionality scenarios
- ImputationCV–based methods are better
 - Imputation CV-based MSE and MAD overall more reliable
 - MAD captures more complex properties (as expected) ?
- Data properties do impact rank selection
 - Both sparsity and latent dimensionality
 - Tip of the iceberg ?




Multi-modal parcellation of the human striatum

- Most parcellation studies are based on single modality
- Fundamental organization convergent across modalities not known
- Three modalities
 - Resting-state (RS)
 - Probabilistic Diffusion Tractography (PDT)
 - Structural Covariance (SC)
- Context-dependent-clustering (CDC, Gabasova et. al, 2017)
 - Can cluster across contexts (i.e. modalities)
 - Model selection based on several criteria
- Behavioral decoding
- Clinical relevance: VBM analysis Parkinson's and Schizophrenia


N = 324 (164 Female) Human Connectome Project



Multi-modal striatum parcellation





Multi-modal striatum parcellation: model selection




Multi-modal striatum parcellation: selected solution

A Multi-modal clusters ($n = 7$)




B Hemisphere-matched multi-modal clusters




Multi-modal striatum parcellation: selected solution n=7

A Multi-modal clusters ($n = 7$)



B Hemisphere-matched multi-modal clusters




Behavioral decoding




Behavioral Domains
Cognition
Perception/Gustation
Emotion
Interception
Action execution

Paradigm classes

Reward
Saccades
Delay discounting
Tower of London
Taste
Isometric force
Flexion/Extension
Finger Tapping
Recitation/Repetition (Overl)
Face Monitor/Discrimination



PD vs. SCZ Averaged Z-scores of GM volume



Ji Chen: SCZ study

Sample details

Characteristics	PHAMOUS sample (N=1545)	International dataset from 9 centers (N=490)	International dataset with imaging (N=147)	Statistics	p-value
Demographic					
Age (years) ^a	44.15 (11.42)	33.82 (10.28)	34.89 (11.67)	183.51	<.001
Gender (male/female)	1108/437	333/157	102/45	2.45	.292
Illness during (years) ^b	18.22 (10.54)	9.13 (8.98)	11.37 (10.36)	134.71	<.001
PANSS					
Positive ^c	12.48 (4.91)	14.24 (5.76)	15.36 (5.50)	37	<.001
Negative	14.60 (6.20)	14.67 (7.21)	15.07 (6.06)	0.375	.687
General ^d	26.70 (8.16)	29.10 (11.34)	30.93 (10.97)	23.67	<.001
Illness severity (Total PANSS) ^e	53.78 (16.35)	58.01 (21.87)	61.36 (19.57)	19.48	<.001
P3 item (hallucinations) ^f	2.30 (1.47)	2.66 (1.83)	3.22 (1.91)	28.18	<.001
Medication^g					
Atypical antipsychotics	NA	167 (34.1%)	110 (74.8%)		
Typical antipsychotics	NA	26 (5.3%)	8 (5.4%)		
Both A & T	NA	16 (3.3%)	9 (6.1%)		
None or unknown	NA	281 (57.3%)	20 (25.9%)		
Current antipsychotic medication ^h	NA	19.64 (14.15)	19.30 (12.57)		

Samples: sex prediction

HCP functional imaging parameters:

Siemens 3T Skyra scanner, 1200 volumes, voxel size= $2 \times 2 \times 2 \text{ mm}^3$, FoV= $208 \times 180 \text{ mm}^2$, 72 slices, TR = 720 ms; TE= 33.1 ms, FA=52°)

- Sample 1: 434 subjects (217 males, age range: 22-37, mean age: 28.6 years),
- Sample 2: 310 subjects (155 males, age range: 22-36, mean age: 28.5 years).

1000 brains functional imaging parameters:

Siemens 3T TRIO scanner, 297 volumes, voxel size= $3.1 \times 3.1 \times 3.1 \text{ mm}^3$, FoV= $200 \times 200 \text{ mm}^2$, 36 slices, TR = 2200 ms; TE= 30 ms, FA=90°)

- Sample: 1115 subjects (508 males, age range: 18-88, mean age: 63.5 years)

SCZ study

Sample details

- Slide Text

Cohort imaging: Large, multi-modal datasets



Initial sample: 131 subjects
Enhanced sample: 900+ subjects
45 publications



900 related subjects
17 publications



1,000+: Schizophrenia, Parkinson
Major Depression, Stroke
50+ publications



1,100 subjects
Longitudinal design
7 publications



10,000 subjects currently
30,000 subjects final



>1,000 subjects currently
15,000 subjects final



10,000 subjects currently
100,000 subjects final